Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial-论文-万方医学网

首页> > Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

导出原文传递

翻译打印收藏纠错

第一作者： Aghajanian, Carol

作者： Aghajanian, Carol ^[1] ; Bookman, Michael A. ^[2] ; Fleming, Gini F. ^[3] ; Swisher, Elizabeth M. ^[4] ; Steffensen, Karina D. ^[5] ; Friedlander, Michael ^[6] ; Okamoto, Aikou ^[7] ; Jackson, Camille Gunderson ^[8] ; Sullivan, Danielle ^[9] ; Ratajczak, Christine K. ^[10] ; Coleman, Robert L.

作者单位： Mem Sloan Kettering Canc Ctr ^[1] Kaiser Permanente Northern Calif ^[2] Univ Chicago Med ^[3] Univ Washington ^[4] Vejle Univ Hosp Southern Denmark ^[5] Prince Wales Clin Sch UNSW ^[6] Sch Med,Jikei Univ ^[7] Hlth Sci Ctr,Univ Oklahoma ^[8] AbbVie Inc ^[9] US Oncol Res ^[10]

关键词 Ovarian cancer Phase 3 Veliparib PARP inhibitor VELIA GOG-3005 BICR THERAPY

发布时间 2022-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

相似文献

同项目论文

相关期刊

检索历史 清除

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

相似文献

同项目论文

相关期刊

检索历史清除